What single agent does the new ASCO guideline recommend for first-line treatment of patients with stage IV non-small-cell lung cancer without positive markers but with high PD-L1 expression? Is there an age limit for use of SBRT for early-stage lung cancer? Test your knowledge in our latest quiz.
Is there an age limit for use of stereotactic body radiation therapy (SBRT) for early-stage lung cancer? What single agent does the new American Society of Clinical Oncology (ASCO) guideline recommend for first-line treatment of patients with stage IV non-small-cell lung cancer (NSCLC) without positive markers but with high programmed death ligand 1 (PD-L1) expression? Test your knowledge in our latest quiz.
According to the ASCO guideline, if a patient has low PD-L1 expression, standard chemotherapy should be offered. For second-line treatment, single-agent atezolizumab, nivolumab, or pembrolizumab may be used if the first-line regimen did not contain immune checkpoint therapy. Crizotinib is recommended for patients with ROS1 gene rearrangement who received no prior crizotinib therapy.
According to the report, the median age of the patients was 62 years; the majority (71%) were never smokers and presented with advanced disease at diagnosis. Median survival for the 12 patients who received HER2-targeted therapies was 2.1 years vs 1.4 years for the 12 patients who did not (P = .48). The authors noted that “HER2-directed therapies should be investigated in this subgroup of patients.”
D. Recent smokers
Recent smokers had a hazard ratio (HR) of 0.38 (P P P = .0208 and HR, 1.62; P = .236) and never smokers (HR, 1.025; P = .971 and HR, 1.33; P = .638), respectively. “Sequencing data revealed that mutational burden was not associated with veliparib benefit,” the study concluded.
A. Median overall survival was similar between both arms
The study authors concluded, “The addition of palifosfamide to carboplatin and etoposide failed to improve survival in early-stage SCLC.” Serious adverse events did not differ significantly between the two arms.
A. Higher rate of grade 3 or higher pneumonitis
The grade 3 or higher pneumonitis rate was 1.3% vs 1.6% vs 1.5% (P = 1.0) in patients aged